Skip to main content

Table 1 Subject characteristics of all the patients recruited for the smoking cessation.

From: Elevation of sputum matrix metalloproteinase-9 persists up to 6 months after smoking cessation: a research study

  Non-smoking controls Asymptomatic Smokers Smokers with smokers Chronic asthma bronchitis/COPD
Subjects (n) 30 25 15 21
Female/male 7/23 15/10 9/6 14/7
Age yrs 56 ± 8 42 ± 12 42 ± 12 56 ± 10
Pack-yrs 4 ± 8 23 ± 15 22 ± 14 39 ± 15
Post-bronchodilator    
FVC L** 4.9 ± 0.71 3.9 ± 0.60 4.2 ± 0.70 3.0 ± 0.66
FVC % pred 102 ± 9 99 ± 14 103 ± 17 102 ± 38
FEV1 L** 4.0 ± 0.65 3.2 ± 0.49 3.5 ± 0.55 2.1 ± 0.72
FEV1% pred* 104 ± 12 97 ± 8 99 ± 14 79 ± 8
FEV1/FVC 82 ± 4.4 83 ± 1 80 ± 9 69 ± 15
  1. Data presented as mean ± SD or median (range). FVC: forced vital capacity; % pred: % predicted; FEV1: forced expiratory volume in one second; *: p < 0.01; **: p < 0.001. #: baseline levels at once after smoking cessation.